Trump Pick to Lead NIH Bhattacharya Vows to Tackle Chronic Disease
Bhattacharya backs vaccines despite past COVID criticism; Senators question Bhattacharya on vaccines, funding cuts; Bhattacharya expected to be confirmed after Senate hearing. His views clash with mainstream public health leaders and pose challenges for the NIH's funding and research integrity. As a vocal critic of lockdowns, Bhattacharya may face skepticism from experts over his approach to tackling chronic diseases.
- The NIH under Bhattacharya's leadership will likely prioritize research on prevention rather than cure, potentially shifting the agency's focus away from established treatments and towards unproven therapies.
- How will the NIH's renewed emphasis on scientific dissent impact the development of vaccines for emerging infectious diseases, such as Ebola or COVID-19?